I think this failure of a competitor's product is a perfect example of why a really big BP cannot let the IPIX pipeline escape their grasp. It is almost unheard of for one company to have so many drugs able to treat such a broad spectrum of ailments, diseases, and conditions and for these uses to all be in the multi-billion dollar range in sales per year.

I have to believe our deal making position is getting stronger by the day. It now should seriously be in the realm of "how can BP even think about letting this power-packed pipeline" escape their grasp to a competitor?

Would like to know if the failure was due to safety or efficacy?